Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).
about
Perspectives and limitations of gene expression profiling in rheumatology: new molecular strategiesA roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung diseaseTumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety.Higher C-reactive protein and soluble tumor necrosis factor receptor levels are associated with poor physical function and disability: a cross-sectional analysis of a cohort of late middle-aged African Americans.Gene transfer to human joints: progress toward a gene therapy of arthritisSeven year changes in health status and priorities for improvement of health in patients with rheumatoid arthritisUpdated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.Biological drug use: US perspectives on indications and monitoring.Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium.Does anti-tumour necrosis factor alpha treatment modify the tuberculin PPD response?
P2860
Q24805489-40D0F086-358A-4226-B6ED-07B10CCDFA6EQ27014138-8514242A-0AEA-4C60-932E-585A6B0E2C42Q33328963-C7953156-1752-47EE-B417-80C84A2C91BEQ33654592-9F4F71CA-F4F8-4875-949E-ED766019E298Q33853972-934BD2F1-223E-46CF-BF9F-3F677B90E2ACQ35555243-B2726064-8D01-4DA7-933B-41C9B2330E3BQ35579352-B3AE7A1F-C8B4-4AA5-8C47-A72D3424ED06Q35579491-CA74D2C5-0AAD-45F8-8583-BF28DC9D8C83Q36575283-13A557E0-D76F-4F02-8606-925E24D4141CQ36930700-18775C7F-637D-4C68-B577-611EE733C902Q42955982-BE5BFC8F-690F-44E3-8A9D-13094ED17282
P2860
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Updated consensus statement on ...... lammatory diseases (May 2003).
@ast
Updated consensus statement on ...... lammatory diseases (May 2003).
@en
Updated consensus statement on ...... lammatory diseases (May 2003).
@en-gb
type
label
Updated consensus statement on ...... lammatory diseases (May 2003).
@ast
Updated consensus statement on ...... lammatory diseases (May 2003).
@en
Updated consensus statement on ...... lammatory diseases (May 2003).
@en-gb
prefLabel
Updated consensus statement on ...... lammatory diseases (May 2003).
@ast
Updated consensus statement on ...... lammatory diseases (May 2003).
@en
Updated consensus statement on ...... lammatory diseases (May 2003).
@en-gb
P2093
P2860
P1476
Updated consensus statement on ...... flammatory diseases (May 2003)
@en
P2093
A F Kavanaugh
A Gibofsky
A S Russell
E C Keystone
F C Breedveld
G R Burmester
J R Kalden
J S Smolen
L B A van de Putte
P2860
P356
10.1136/ARD.62.SUPPL_2.II2
P407
P478
62 Suppl 2
P577
2003-11-01T00:00:00Z